A detailed history of Altium Capital Management LP transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Altium Capital Management LP holds 1,360,000 shares of ADMA stock, worth $23.7 Million. This represents 9.59% of its overall portfolio holdings.

Number of Shares
1,360,000
Previous 1,510,000 9.93%
Holding current value
$23.7 Million
Previous $16.9 Million 61.04%
% of portfolio
9.59%
Previous 8.99%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$11.21 - $20.03 $1.68 Million - $3 Million
-150,000 Reduced 9.93%
1,360,000 $27.2 Million
Q2 2024

Aug 14, 2024

SELL
$5.98 - $11.18 $179,400 - $335,400
-30,000 Reduced 1.95%
1,510,000 $16.9 Million
Q1 2024

May 15, 2024

BUY
$4.4 - $6.74 $1.96 Million - $3 Million
445,000 Added 40.64%
1,540,000 $10.2 Million
Q4 2023

Feb 14, 2024

SELL
$3.08 - $4.52 $5.01 Million - $7.36 Million
-1,628,011 Reduced 59.79%
1,095,000 $4.95 Million
Q3 2023

Nov 14, 2023

BUY
$3.47 - $4.61 $1.19 Million - $1.58 Million
343,011 Added 14.41%
2,723,011 $9.75 Million
Q2 2023

Aug 14, 2023

SELL
$3.12 - $4.22 $1.53 Million - $2.07 Million
-490,000 Reduced 17.07%
2,380,000 $8.78 Million
Q4 2022

Feb 14, 2023

SELL
$2.47 - $3.88 $33,863 - $53,194
-13,710 Reduced 0.48%
2,870,000 $11.1 Million
Q3 2022

Nov 14, 2022

SELL
$2.03 - $2.86 $2.27 Million - $3.19 Million
-1,116,290 Reduced 27.91%
2,883,710 $7.01 Million
Q2 2022

Aug 15, 2022

BUY
$1.43 - $2.2 $1 Million - $1.54 Million
700,000 Added 21.21%
4,000,000 $7.92 Million
Q3 2021

Nov 15, 2021

BUY
$1.13 - $1.65 $3.73 Million - $5.45 Million
3,300,000 New
3,300,000 $4.65 Million

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $3.42B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.